Surfactant
Phase 3Small molecule
Surfactant is one of 8 small molecule programs targeting Adult Acute Respiratory Distress Syndrome. It is currently in Phase 3.
3
Indications
14
Total Trials
2
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Adult Acute Respiratory Distress Syndrome
#DrugCompanyPhaseTrials
1Remodulin
United TherapeuticsApproved
Daliresp
AstraZenecaApproved
Caverject
VViatris Specialty LLC
Approved
Aurlumyn
BBTG International Inc.
Approved
Surfactant
NNICHD Neonatal Research Network
Phase 3
Aldactone
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Respiratory Distress Syndrome1 trial
Newborn Respiratory Distress Syndrome1 trial
Adult Acute Respiratory Distress Syndrome1 trial
7 more indications
Neonatal respiratory distress1 trial
Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study
Unknown status·—··NCT03479450·200 enrolled
Lung Transplantation1 trial
Altitude1 trial
Pulmonary Surfactant(PS) Therapy at High Altitude Area
Completed·—··NCT03440333·400 enrolled
Infants1 trial
Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS
Unknown status·—·Phase 2·NCT01723683·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Surfactant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNICHD Neonatal Research Network